{
    "root": "2b425f68-5939-4195-a281-393b10eba889",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "IZERVAY",
    "value": "20250306",
    "ingredients": [
        {
            "name": "AVACINCAPTAD PEGOL SODIUM",
            "code": "K86ENL12I5"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE",
            "code": "70WT22SF4B"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
            "code": "593YOG76RN"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        }
    ],
    "indications": "IZERVAY™ is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).",
    "contraindications": "The recommended dose for IZERVAY is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately 28 ± 7 days) ( 2.2 ).",
    "warningsAndPrecautions": "IZERVAY (avacincaptad pegol intravitreal solution) is supplied as a sterile, clear to slightly opalescent, colorless to slightly yellowish 20 mg/mL solution in a single-dose glass vial. Each glass vial contains an overfill amount to allow administration of a single 0.1 mL dose of solution containing 2 mg of avacincaptad pegol (oligonucleotide basis). Each IZERVAY carton (NDC 82829-002-01) contains one glass vial, one sterile 5-micron transfer filter needle (18-gauge x 1½ inch, 1.2 mm x 40 mm), and one sterile 1 mL Luer lock syringe.",
    "adverseReactions": "• Ocular or periocular infections ( 4.1 ). • Active intraocular inflammation ( 4.2 )."
}